Document is current
Any future updates will be listed below
-
Authors
Fuji, Shigeo https://orcid.org/0000-0001-5118-7950
Hakoda, Akitoshi https://orcid.org/0000-0001-5058-9296
Kanda, Junya https://orcid.org/0000-0002-6704-3633
Murata, Makoto https://orcid.org/0000-0001-5488-4364
Terakura, Seitaro https://orcid.org/0000-0002-1194-8046
Inamoto, Yoshihiro https://orcid.org/0000-0003-4881-0427
Uchida, Naoyuki https://orcid.org/0000-0001-5952-5926
Toya, Takashi https://orcid.org/0000-0002-7436-972X
Eto, Tetsuya
Nakamae, Hirohisa https://orcid.org/0000-0003-4203-990X
Ikegame, Kazuhiro https://orcid.org/0000-0002-5421-7470
Tanaka, Masatsugu
Kawakita, Toshiro
Kondo, Tadakazu https://orcid.org/0000-0002-8959-6271
Miyamoto, Toshihiro https://orcid.org/0000-0002-6533-1594
Fukuda, Takahiro
Ichinohe, Tatsuo https://orcid.org/0000-0002-0393-4066
Kimura, Takafumi
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Shintani, Ayumi
Morishima, Satoko https://orcid.org/0000-0002-7391-4271
- License Information
-
More Information
Article History
Received: 5 January 2021
Revised: 5 August 2021
Accepted: 19 August 2021
First Online: 3 September 2021
Competing interests
: HN received honoraria from Amgen Astellas BioPharma K.K., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa-Hakko Kirin Co., Ltd., Shire Japan KK., Celgene Corporation, Daiichi Sankyo Company., Ltd., Takeda Pharmaceutical Company Limited., Chugai Pharmaceutical Co., Ltd., Japan Blood Products Organization, Nippon Shinyaku Co., Ltd., Novartis, Pfizer Japan Inc, Bristol-Myers Squibb Company, and research funding from Astellas Pharma Inc, Otsuka Pharmaceutical Co. Ltd., Novartis and Bristol-Myers Squibb Company.
